The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) has said that single dose of Stelara (ustekinumab) has induced clinical remission and response in adults with moderate to severe ulcerative colitis (UC).
The National Institute for Health Research (NIHR) said that the first clinical trial of a novel approach to modify the progression of Alzheimer’s disease has commenced at the NIHR University College London Hospitals (UCLH) Clinical Research Facility.
Bial and Eisai said that Zebinix (eslicarbazepine acetate) as monotherapy has been confirmed in the Euro-Esli study to be significantly effective than the same drug as adjunctive therapy for focal-onset epilepsy in adults.
UK-based specialty pharma company Diurnal Group said that its adrenal drug Chronocort failed to meet the primary objective of a phase 3 trial in adults with congenital adrenal hyperplasia (CAH).
hVIVO, is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases, has signed two new contracts with global biopharmaceutical company for two respiratory syncytial virus (RSV) human challenge studies.
Merck’s HIV Therapy Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate) has achieved primary efficacy endpoint in phase 3 Drive-Shift study, which is assessing switch to Delstrigo from other antiretroviral treatment regimens.
Eli Lilly and Company (Lilly) and Boehringer Ingelheim said that their SGLT2 inhibitor empagliflozin has met the primary efficacy endpoint of a phase III program in adults with type 1 diabetes.
Gilead Sciences has reported 96-week results from a phase 3, randomized, double-blinded study evaluating the safety and efficacy of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) for the treatment of HIV-1 infection in treatment-naïve adults.
Alnylam Pharmaceuticals has filed a clinical trial authorization (CTA) application to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to start a phase 1/2 trial of ALN-AAT02 for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (alpha-1 liver disease).
Inotrem said that a phase IIa study demonstrated the safety and tolerability of nangibotide (LR12), its lead product candidate, in the treatment of septic shock patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.